The oral drug technology developer, which is backed by corporates including Alphabet, Novartis and AstraZeneca, has now raised $100m in total.

The genetics services company, which is backed by Alphabet, Illumina, WuXi PharmaTech and Johnson and Johnson, has now raised more than $490m altogether.

Merck Group and Illumina were among the investors in a $13.2m round, along with Idinvest Partners, Kurma Partners and existing backer Sofinnova Partners.

Antidote Technologies, developer of a recruitment platform for clinical trials, has agreed an $11m round that will be led by Merck Global Health Innovation Fund.

Existing backer SoftBank has helped on-demand therapy service Talkspace close a $31m series C round that increased its total funding to $59m since 2014.

Merck-backed nerve stimulation device producer ElectroCore has raised new funding, according to a securities filing that shows the company is seeking a $65m close.

University of Geneva spinout Amal Therapeutics has added $9.6m to its coffers following a series B round backed by Boehringer Ingelheim and Helsinn.

Wuxi NextCode has achieved a final close of its Amgen Ventures-backed series B round at $240m with additional commitments from investors including Temasek.